药物类别在药物诱导性皮肌炎中的差异:一项系统综述
该系统综述检索 Pubmed、EMBASE 和 MEDLINE 的英文文献,纳入 69 例已发表的药物诱导性皮肌炎(DIDM)病例,其中生物制剂相关 33 例、传统药物相关 36 例,41 例有既往恶性肿瘤史。羟基脲诱导病例无肌肉损伤,抗 TIF1-γ 抗体主要见于生物制剂诱导病例,且仅在主要诊断为恶性疾病并随后暴露于免疫检查点抑制剂的病例中报告。
要点
- 共纳入 69 例已发表 DIDM 病例,生物制剂相关 33 例,传统药物相关 36 例。
- 41 例 DIDM 病例有既往恶性肿瘤史。
- 羟基脲诱导病例无肌肉损伤,抗 TIF1-γ 抗体主要见于生物制剂诱导病例。
核心结论
- 本综述汇总了当前关于 DIDM 的文献,强调致病药物谱在不断演变,并阐明了不同药物诱导病例在临床表现、实验室检查和潜在机制方面的差异。
研究设计与样本
- 系统综述,检索 Pubmed、EMBASE 和 MEDLINE 的英文文献,纳入 69 例已发表的 DIDM 病例,其中生物制剂相关 33 例、传统药物相关 36 例。
主要发现
- 69 例 DIDM 病例中,33 例归因于生物制剂,其余 36 例归因于传统药物。
- 69 例 DIDM 病例中有 41 例有既往恶性肿瘤史。
- DIDM 病例的皮肤和肌肉表现与经典 DM 相似,但羟基脲诱导病例无肌肉损伤。
- 抗核抗体阳性和抗 TIF1-γ 自身抗体主要在生物制剂诱导病例中观察到,而抗 TIF1-γ 抗体仅在主要诊断为恶性疾病并随后暴露于免疫检查点抑制剂的病例中报告。
关键数值与推荐
- 抗 TIF1-γ 抗体可能作为识别 DM 患者合并恶性疾病的警示信号。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Drug-induced dermatomyositis (DIDM) is a rare and underestimated variant of dermatomyositis (DM) characterized by muscle damage and skin rash and related to certain drug exposure. The spectrum of drugs causing DIDM has evolved over time, originally implicating hydroxyurea, penicillamine, and statins as causative agents. Tumor necrosis factor α inhibitors and immune checkpoint inhibitors have also been associated with such conditions. To bridge the gap between current literature and clinical practice, and therefore guide clinicians, we conducted a comprehensive review of English literature from Pubmed, EMBASE, and MEDLINE. Our analysis included demographic data, clinical features, laboratory findings, therapeutic outcomes, and extant research pertaining to the probable pathogenesis of DIDM induced by various drugs. Furthermore, we categorized the drugs involved in DIDM cases into biologics and traditional agents for subsequent statistical analysis. Over time, there has been a gradual accumulation of reported DIDM cases. A total of 69 published DIDM cases were documented in our study, among which 33 should be attributed to biologics and the remaining 36 to traditional drugs. Interestingly, 41 of all DIDM cases had a previous history of malignancies. Additionally, DIDM cases exhibited similar cutaneous and muscular manifestations to classic DM, with the exception of cases induced by hydroxyurea, which did not entail muscle damage. Positive antinuclear antibodies and anti-TIF1-γ autoantibodies have been predominantly observed in biologics-induced cases, while positive anti-TIF1-γ antibodies were merely reported in the cases that were primarily diagnosed with malignant diseases and exposed to ICIs afterwards. Anti-TIF1-γ antibodies may potentially serve as a red flag in the identification of co-existing malignant diseases in DM patients. We also provided a comprehensive summary and exploration of potential mechanisms lying behind drug-induced dermatomyositis. In conclusion, our review consolidates the current literature on DIDM, highlighting the evolving spectrum of medications and elucidating the differences in clinical manifestations, laboratory findings, and underlying mechanisms.
引用
- Yu K, Wang T, An D, et al. Investigating the disparities among drug categories in drug-induced dermatomyositis: A systematic review. Semin Arthritis Rheum. 2024. PMID: 38833729. doi:10.1016/j.semarthrit.2024.152478
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。